p38 MAPK

MAPK

p38 MAPK

p38 MAPK Isoform Specific Products:

p38 MAPK Related Products (473)
Recombinant Proteins (3)
Antibodies (20)
p38 MAPK Isoform Comparison

By Effects:	Control (1) Inhibitors (339) Agonists (2) Degrader (1) Activators (79) Modulators (4) p53 Inhibitor (1) Inducers (8)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-W728531

Ac4ManNAz	Inhibitor	99.52%
Ac4ManNAz can be taken up by cells and is an azide-containing metabolic glycoprotein labeling reagent that selectively modifies proteins. Commonly used for cell labeling, tracking and proteomic analysis. Ac4ManNAz contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Ac4ManNAz can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-123942

Diprovocim	Agonist	98.82%
Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses.

HY-W015883

Fumaric acid	Inhibitor	99.91%
Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension.

HY-18260

Bisphenol A		99.75%
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cancers, cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.

HY-113342

7-Ketocholesterol	Activator	99.87%
7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis).

HY-139414

Lysophosphatidylcholines		≥99.0%
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis.

HY-112089

Naporafenib	Inhibitor	99.86%
Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC₅₀ values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.

HY-13241

Ralimetinib dimesylate	Inhibitor	99.91%
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-B0647

Butylphthalide	Activator	99.98%
Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.

HY-N0270

Ononin	Inhibitor	99.96%
Ononin is an orally active isoflavone. Ononin inhibits the ERK/JNK/p38 and PI3K/Akt/mTOR pathways. Ononin regulates Apoptosis. Ononin has anti-tumor effects on laryngeal cancer and lung cancer. Ononin has neuroprotective effects. Ononin alleviates endoplasmic reticulum stress and diabetic nephropathy.

HY-10328

Neflamapimod	Inhibitor	99.32%
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

HY-10402

Losmapimod	Inhibitor	99.94%
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively.

HY-N0674

Dehydrocorydaline	Activator	99.77%
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline shows strong anti-malarial effects (IC₅₀=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

HY-N0568

Madecassoside	Inhibitor	99.58%
Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB^[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

HY-10261A

Afatinib dimaleate	Inhibitor	99.74%
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-147268

Exarafenib	Inhibitor	99.68%
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity.

HY-111431

p-Cresyl sulfate	Activator	99.87%
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways.

HY-10401

VX-702	Inhibitor	99.54%
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.

HY-14654R

Aspirin (Standard)	Activator	99.85%
Aspirin (Standard) is the analytical standard of Aspirin. This product is intended for research and analytical applications. Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.

HY-N0031

Plantamajoside		99.52%
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects.

Adezmapimod	p38, IC₅₀: 50 nM		p38β2, IC₅₀: 500 nM				99.96%
SB 202190		p38α, IC₅₀: 50 nM	p38β2, IC₅₀: 100 nM				99.89%
Doramapimod	p38 MAP kinase, Kd: 0.1 nM	p38α, IC₅₀: 38 nM	p38β, IC₅₀: 65 nM		p38δ, IC₅₀: 520 nM	p38γ, IC₅₀: 200 nM	99.98%
NR-11c		p38α					99.75%
Adezmapimod hydrochloride	p38, IC₅₀: 50 nM		p38β2, IC₅₀: 500 nM				99.71%
Muramyl dipeptide	p38 MAPK						≥98.0%
Diprovocim	p38 MAPK						98.82%
Naporafenib		p38α, IC₅₀: 2.1 μM					99.86%
Ralimetinib dimesylate		p38α MAPK, IC₅₀: 5.3 nM	p38β MAPK, IC₅₀: 3.2 nM				99.91%
Neflamapimod		p38α, IC₅₀: 10 nM	p38β, IC₅₀: 220 nM				99.32%
Exarafenib	p38 MAPK						99.68%
Skatole	p38						99.97%
Esculin	p38 MAPK						99.47%
Talmapimod		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM				98.97%
p38 MAPK-IN-1	p38 MAPK, IC₅₀: 68 nM						99.58%
Tpl2 Kinase Inhibitor 1	p38, IC₅₀: 180 μM						99.22%
SB 202190 hydrochloride		p38α, IC₅₀: 50 nM	p38β2, IC₅₀: 100 nM				99.84%
Semapimod tetrahydrochloride	p38 MAPK						98.43%
Paris saponin VII	p38						99.96%
AMG-548 dihydrochloride		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM	99.91%
Broussonin E	p38 MAPK						98.18%
Peimine	p38						99.43%
TAK-715		p38α, IC₅₀: 7.1 nM	p38β, IC₅₀: 200 nM		p38δ, IC₅₀: >10 μM	p38γ, IC₅₀: >10 μM	99.76%
Gossypetin	p38 MAP kinase						99.82%
MAPK13-IN-1				MAPK13 (p38δ), IC₅₀: 620 nM			98.93%
Dihydrocaffeic acid	p38 MAPK						99.65%
UM-164		p38α	p38β				99.15%
Teneligliptin hydrobromide	p38 MAPK						99.99%
Pamapimod		p38α, IC₅₀: 14 nM p38α, Ki: 1.3 nM	p38β, IC₅₀: 480 p38β, Ki: 120 nM				99.92%
Cornuside	p38 MAP kinase						99.99%
NF-κB/MAPK-IN-1	p38						98.42%
SM-7368	p38 MAP kinase						99.77%
Ferulic acid methyl ester	p38						99.95%
EW-7195		p38α, IC₅₀: 1.5 μM					98.84%
Emprumapimod		p38α					99.04%
BMS-582949 hydrochloride		p38α MAPK, IC₅₀: 13 nM					98.90%
MKK7-COV-9	p38 MAP kinase
Isoliquiritin apioside	p38 MAPK						99.87%
MW-150		p38α, Ki: 101 nM					99.89%
SR-318		p38α, IC₅₀: 5 nM	p38β, IC₅₀: 32 nM				99.89%
R1487 Hydrochloride		p38α, Kd: 0.2 nM	p38β, Kd: 29 nM				99.33%
TA-01	p38 MAP kinase, IC₅₀: 6.7 nM						99.86%
RWJ-67657		p38α, IC₅₀: 1 μM	p38β, IC₅₀: 11 μM				99.75%
N-Feruloyloctopamine	p38 MAPK						99.91%
JNJ-49095397		p38α				p38γ	99.85%
SJFα		p38α, DC₅₀: 7.16 nM			p38δ, DC₅₀: 299 nM		99.61%
PF-05381941		p38α, IC₅₀: 186 nM					99.73%
p38α inhibitor 2		p38α MAPK, pIC₅₀: 9.6					98.03%
Rotundic acid	p38 MAPK						99.41%
Anti-inflammatory agent 35	p38 MAPK						99.77%
p38 MAP Kinase Inhibitor III	p38 MAP kinase, IC₅₀: 0.9 μM						98.77%
SD-169		p38α MAPK, IC₅₀: 3.2 nM	p38β MAPK, IC₅₀: 122 nM				99.91%
p38 MAP Kinase Inhibitor IV		p38α, IC₅₀: 0.13 μM	p38β, IC₅₀: 0.55 μM		p38δ, IC₅₀: 8.63 μM		98.0%
AMG-548		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM	≥99.0%
p38 MAPK-IN-4	p38, IC₅₀: 35 nM						98.45%
p38α inhibitor 1		p38α					98.91%
AL 8697		p38α, IC₅₀: 6 nM	p38β, IC₅₀: 82 nM				99.83%
Emprumapimod hydrochloride		p38α					≥98.0%
SB 220025	p38, IC₅₀: 60 nM						99.90%
SX 011		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM		p38δ, IC₅₀: > 300 (Pan)	p38γ, IC₅₀: > 300 (Pan)	99.33%
Sugiol	p38 MAPK						99.88%
MW-150 hydrochloride		p38α, Ki: 101 nM
MW-150 dihydrochloride dihydrate		p38α, Ki: 101 nM
Ralimetinib		p38α MAPK, IC₅₀: 5.3 nM	p38β MAPK, IC₅₀: 3.2 nM
Talmapimod hydrochloride		p38α, IC₅₀: 9 nM	p38β, IC₅₀: 90 nM
Casein kinase 1δ-IN-27		p38α, IC₅₀: 14.8 nM
p38-α MAPK-IN-4		p38α MAPK, IC₅₀: 1.5 μM
Casein kinase 1δ-IN-29		p38α, IC₅₀: 0.041 μM
Halociline	p38 MAP kinase
SJFδ		p38α, DC₅₀: 46.17 nM
p38-α MAPK-IN-5		p38α, IC₅₀: 0.1 nM	p38β, IC₅₀: 0.2 nM		p38δ, IC₅₀: 4100 nM	p38γ, IC₅₀: 944 nM
p38 MAPK-IN-3		p38α MAPK
SB-284851-BT		p38α, Kd: 0.47 nM
J-1149		p38α MAPK
p38α inhibitor 7		p38α
MW108 hydrochloride		p38α MAPK, Ki: 114 nM
p38α-MK2-IN-1		p38α
DCZ19931	p38 MAPK
Lucidone	p38 MAPK
AMG-548 hydrochloride		p38α, Ki: 0.5 nM dog p38α, Ki: 5.0 nM	p38β, Ki: 3.6 nM		p38δ, Ki: 2600 nM	p38γ, Ki: 4100 nM
CHMFL-ABL-053	p38, IC₅₀: 62 nM
Semapimod	p38 MAPK
NDs-IN-1	p38 MAPK
(aS)-PH-797804		p38α, IC₅₀: 26 nM	p38β, IC₅₀: 102 nM
JNK3 inhibitor-5		p38α, IC₅₀: 215.8 nM
Balanophonin	p38
Doramapimod (GMP)		p38α, IC₅₀: 38 nM	p38β, IC₅₀: 65 nM		p38δ, IC₅₀: 520 nM	p38γ, IC₅₀: 200 nM
PF-03715455		p38α, IC₅₀: 0.88 nM	p38β, IC₅₀: 23 nM
SR-302		p38α, IC₅₀: 125 nM
BMS-582949		p38α, IC₅₀: 13 nM
CK1δ-IN-9		p38α, IC₅₀: 0.25 μM	p38β, IC₅₀: 0.78 μM
Cudraflavone B	p38 MAP kinase
p38α inhibitor 4		p38α, IC₅₀: 1.2 μM
Casein kinase 1δ-IN-31		p38α, IC₅₀: 18 nM
p38α inhibitor 8		p38α, IC₅₀: 0.21 μM
p38-α MAPK-IN-10		p38α, IC₅₀: 4 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

p38 MAPK

p38 MAPK

p38 MAPK Isoform Specific Products:

p38 MAPK Isoform Specific Products:

p38 MAPK Related Products (473)

Recombinant Proteins (3)

Antibodies (20)

p38 MAPK Isoform Comparison

p38 MAPK Related Products (473):